Eli Lilly to supply limited patients with retatrutide ahead of approval
LLY Lilly(Eli) & Co
$1115.68 -0.51%
차트·분석 보기 → - 1Eli Lilly (LLY) will supply its experimental obesity drug retatrutide to a limited number of patients prior to U.S. approval.
- 2The program targets patients aged 18 and older with treatment-resistant obesity despite the highest existing dose, who also have two or more severe comorbidities and are unable to enroll in clinical trials.
- 3Retatrutide targets three hormones, showed an average 22.6% reduction at the highest dose in an 80-week trial in July, and the company plans to file for approval in the first quarter of next year.
This 3-line summary is compiled from the report below.
Bloomberg +1 View original ↗🎯 오늘의 AI 픽 5종목, 무료로 전부 공개합니다
숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다